Enhancement of glutamate uptake in 1-methyl-4-phenylpyridinium-treated astrocytes by trichostatin A

NeuroReport

Volumn 19, Issue 12, 2008, Pages 1209-1212

  Wu, Jia Yong ^a,b   Niu, Feng Nan ^a,b   Huang, Rong ^a,b   Xu, Yun ^a,b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b NANJING UNIVERSITY   (China)

Author keywords

Astrocyte; Glutamate transporters; Histone deacetylase inhibitors; Neuroprotection

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; HISTONE DEACETYLASE INHIBITOR; TRICHOSTATIN A; VESICULAR GLUTAMATE TRANSPORTER 1; ENZYME INHIBITOR; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; HISTONE DEACETYLASE; HYDROXAMIC ACID;

AMINO ACID TRANSPORT; ANIMAL CELL; ARTICLE; ASTROCYTE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL RATE; WESTERN BLOTTING; ANIMAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; UPREGULATION; WISTAR RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ASTROCYTES; BLOTTING, WESTERN; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; EXCITATORY AMINO ACID TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; GLUTAMIC ACID; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; RATS; RATS, WISTAR; UP-REGULATION;

EID: 51649088278     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e328308b355     Document Type: Article

References (21)

1. Balakin KV, Ivanenkov YA, Kiselyov AS, Tkachenko SE. Histone deacetylase inhibitors in cancer therapy: latest developments, trends, and medicinal chemistry perspective. Anticancer Agents Med Chem 2007; 7:576-592.
2. Kozikowski AP, Chen Y, Gaysin A, Chen B, D'Annibale MA, Suto CM, et al. Functional Differences in Epigenetic Modulators-Superiority of Mercaptoacetamide-Based Histone Deacetylase Inhibitors Relative to Hydroxamates in Cortical Neuron Neuroprotection Studies. J Med Chem 2007; 50:3054-3061.
3. Kanai H, Sawa A, Chen RW, Leeds P, Chuang DM. Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenom J 2004; 4:336-344.
4. Peng GS, Li G, Tzeng NS, Chen PS, Chuang DM, Hsu YD, et al. Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res Mol Brain Res 2005; 134:162-169.
5. Chen PS, Wang CC, Bortner CD, Peng GS, Wu X, Pang H, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007; 149:203-212.
6. Kim HJ, Rowe M, Ren M, Hong JS, Chen PS, Chuang DM. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J Pharmacol Exp Ther 2007; 321:892-901.
7. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem 2004; 89:1358-1367.
8. Rouaux C, Panteleeva I, Rene F, Gonzalez de Aguilar JL, Echaniz-Laguna A, Dupuis L, et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding protein-dependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 2007; 27:5535-5545.
9. Gardian G, Yang L, Cleren C, Calingasan NY, Klivenyi P, Beal MF. Neuroprotective effects of phenylbutyrate against MPTP neurotoxicity. Neuromolecular Med 2004; 5:235-241.
10. Chen PS, Peng GS, Li G, Yang S, Wu X, Wang CC, et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006; 11:1116-1125.
11. Darlington CL. Astrocytes as targets for neuroprotective drugs. Curr Opin Investig Drug 2005; 6:700-703.
12. Zhou F, Yao HH, Wu JY, Yang YJ, Ding JH, Zhang J, et al. Activation of Group II/III metabotropic glutamate receptors attenuates LPS-induced astroglial neurotoxicity via promoting glutamate uptake. J Neurosci Res 2006; 84:268-277.
13. Yao HH, Ding JH, Zhou F, Wang F, Hu LF, Sun T, et al. Enhancement of glutamate uptake mediates the neuroprotection exerted by activating group II or III metabotropic glutamate receptors on astrocytes. J Neurochem 2005; 92:948-961.
14. Schousboe A, Waagepetersen HS. Role of astrocytes in glutamate homeostasis: implications for excitotoxicity. Neurotox Res 2005; 8:221-225.
15. Hazell AS. Excitotoxic mechanisms in stroke: an update of concepts and treatment strategies. Neurochem Int 2007; 50:941-953.
16. Seifert G, Schilling K, Steinhauser C. Astrocyte dysfunction in neurological disorders: a molecular perspective. Nat Rev Neurosci 2006; 7:194-206.
17. Bown CD, Wang JF, Young LT. Increased expression of endoplasmic reticulum stress proteins following chronic valproate treatment of rat C6 glioma cells. Neuropharmacology 2000; 39:2162-2169.
18. Smeyne RJ, Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain Res Mol Brain Res 2005; 134:57-66.
19. Jayakumar AR, Panickar KS, Murthy CHR, Norenberg MD. Oxidative stress and mitogen-activated protein kinase phosphorylation mediate ammonia-induced cell swelling and glutamate uptake inhibition in cultured astrocytes. J Neurosci 2006; 26:4774-4784.
20. Daosukho C, Chen Y, Noel T, Sompol P, Nithipongvanitch R, Velez JM, et al. Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury. Free Radic Biol Med 2007; 42: 1818-1825.
21. Kalandadze A, Wu Y, Robinson MB. Protein kinase C activation decreases cell surface expression of the GLT-1 subtype of glutamate transporter. Requirement of a carboxyl-terminal domain and partial dependence on serine 486. J Biol Chem 2002; 277:45741-45750.